The Alzheimer Drug Leqembi Drives BioArctic Into the Profit Zone
Reading Time: 4 minutes
Leqembi success drives profit jump : First-time profitability thanks to rapidly growing royalty revenues from worldwide Alzheimer's therapy sales. Technology with billion-dollar potential : BrainTransporter™ platform attracts big pharma partners like Novartis and BMS. The Swedish biopharma company BioArctic has established itself in recent years as an innovator in the fight against neurodegenerative diseases. The focus is on highly specialized antibody therapies for the treatment of Alzheimer’s, Parkinson’s, and other serious neurological...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
